Apptly Announces $1,000,000 Non-Brokered Private Placement 
SATO Technologies Corp. Announces Loan Settlement Eliminating All of Its Senior Secured Debt and C$1.5 Million Private Placement 
Theralase(R) Closes C$3.6 Million Brokered Financing Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) — Krystal…
U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market…
Cage-Free Repair Releases 2023 Cannabis Social Responsibility Report
TEMPLE CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Cage-Free Repair announced today that it…
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) — Krystal…
Cage-Free Repair Releases 2023 Cannabis Social Responsibility Report
TEMPLE CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Cage-Free Repair announced today that it…
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Gurnet Point Capital (“Gurnet Point”) and Novo…
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Gurnet Point Capital (“Gurnet Point”) and Novo…
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market…
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market…
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Genprex Inc. (NASDAQ: GNPX)…
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Genprex Inc. (NASDAQ: GNPX)…
Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia
Intelligent Bio Solutions at the 2023 Workplace Health & Safety Show Intelligent Bio Solutions at…
Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia
Intelligent Bio Solutions at the 2023 Workplace Health & Safety Show Intelligent Bio Solutions at…
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
– 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable…
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
– 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable…
Gradalis to Participate in the Cantor Global Healthcare Conference
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, clinical stage biotechnology…